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Purpose: We retrospectively evaluated our experience of transcatheter arterial embolization (TAE) of the sacral GCT
with use of a spherical permanent embolic agent, superabsorbant polymer microsphere (SAP-MS) as an alternative
treatment modality.
Materials and methods: From 1997 to 2011, four patients with sacral GCT were treated with TAE. In all cases,
SAP-MS was used as an embolic material. The effects of TAE were evaluated for improvement of patients’
symptoms, radiographic change such as vascularity of tumor, size of tumor and occurrence of reossification.
Results: Of the four patients, three responded favorably to TAE with improvement in pain and neurologic
symptoms with long-term follow up. Diminished vascularity, stabilization of tumor size and reossification were
shown radiographically. One patient died because of tumor growth 26 months after the initial TAE.
Conclusion: In sacral GCT, TAE using SAP-MS might be useful for symptom improvement, reossification of the
lesion and stabilization of tumor size.
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Giant cell tumor (GCT) of bone is an aggressive benign
neoplasm (Lackman et al. 2002) which occurs most fre-
quently at the end of long bones. The sacrum is the
fourth most common site, accounting for between 1.7–
8.2% of cases (Martin and McCarthy. 2010). With GCT
of long bones, curretage and/or surgical exision is usu-
ally a first-line treatment. However, with sacral GCT, the
size and location of the tumor make surgical treatment
difficult and dangerous.
Therefore, various non-surgical treatment methods
have been advocated including transarterial embolization
(TAE), radiation, and cryotherapy (Martin and McCarthy* Correspondence: je2k-nkns@asahi-net.or.jp
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in any medium, provided the original work is p2010). There have been many reports about arterial
embolization of sacral GCT (Lackman et al. 2002; Martin
and McCarthy 2010; Lin et al. 2002; Hosalkar et al. 2007;
Onishi et al. 2010; Thangaraj et al. 2010).
In these literatures, TAE has mainly been used either
as a method of preoperative devascularization or as a
palliative measure for inoperable lesions. Recently, the
development of permanent spherical embolic materials
such as Hepasphere (Merit Medical, Rockland, MA,
USA), Embosphere (Merit Medical, Rockland, MA, USA),
BeadBlock (Biocompatibles, UK) and so on (Abramowitz
et al. 2009) have been remarkable. These materials have
been widely used for embolization of hepatocellular car-
cinoma, uterine fibroid and arteriovenous malformation
(Abramowitz et al. 2009; Maeda et al. 2012; Osuga et al.
2008; Khankan et al. 2004; Laurent et al. 2004) and so on.
However, to the best of our knowledge, there have been
only a few reports of use of spherical embolic agents foris an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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et al. 2004). We employed spherical permanent embolic
material superabsorbant polymer microsphere (SAP-MS)
for palliative TAE in four cases of sacral GCT for dimin-
ishing vascularity, promoting reossification and as a result,
to accomplish pain relief and improvement of activities of
daily life (ADL).
We retrospectively evaluated the effect of TAE of sa-
cral GCT with SAP-MS.
Materials and methods
Patients
Between 1997 and 2011, four patients (2 males; 2 fe-
males) with sacral GCT underwent TAE 15 times totally
(Table 1). In all patients, the diagnosis of GCT was
confirmed histologically by previous biopsies or oper-
ation. One patient had already undergone radiotherapy
about three months before initial TAE (case 1); one pa-
tient had a recurrent tumor and had undergone curre-
tage about six months before initial TAE (case 4) in a
previous treatment; one patient had undergone radio-
therapy about three months after final TAE as an add-
itional treatment (case 2). Before performing TAE, all
patients complained of skeletal pain which had impaired
their ADL and two patients needed morphine sulfate. In
all patients, International Society of Limb Salvage (ISOLS)
criteria to the lower extremity was less than 50% (Tables 1
and 2) (Enneking et al. 1993).
The mean tumor size was more than 9 cm diameter.
In all cases, the tumors were evaluated as hypervascular
as contrast enhanced dynamic MRI. All cases were
judged as inoperable and TAE was considered to be an
exclusive treatment modality in a palliative setting.
Embolic material properties
SAP-MS is characterized by a spherical shape of uniform
size, deformability, biocompatibility, non-biodegradability
and ease in delivering through microcatheter.
It has a unique property of an ability to absorb fluids
within minutes and increase its diameter. The diameter
in an ionic contrast material (Ioxaglate 320 mg/ml) and
human serum is approximately 2 to 3.5 times larger
than its original size. The particle size, calibrated every
50 μm, ranged from 53 to 350 μm. Animal study showed
limited reactive and inflammatory changes in the arter-
ial wall and surrounding tissue without later recanaliza-
tion (Abramowitz et al. 2009; Maeda et al. 2012; Osuga
et al. 2008; Khankan et al. 2004; Laurent et al. 2004).
SAP-MS was originally invented by one of the co-
authors (Jiaqi et al. 1996), and was approved in June
2013 as Hepasphere in our country, but it was not com-
mercially available at the time we treated these four pa-
tients. Therefore, the prototype material was used
during the study period, and the use of the material inembolization procedures was permitted and approved
by our institutional committee on a patient-by-patient
basis. All patients gave informed consent to undergo the
embolization procedure. The same material had been
already approved as HepaSphere in Europe and Quadra-
Sphere in USA.
This retrospective study was also approved by our in-
stitutional review board (IRB).
Methods
Baseline digital subtraction angiography (DSA) was per-
formed by a 4.2-F diagnostic catheter for identifying the
feeding arteries. After that, a 2.3-F microcatheter was
advanced coaxially into the peripheral portion of each
feeding artery as close to the tumor as possible. Selective
DSA was performed to confirm the feeding arteries were
supplying the target lesion. The embolized arteries in-
cluded the lateral sacral, iliolumbar, fifth lumbar and
medial sacral arteries (Table 1).
Neither systemic analgestic sedation nor prophylatic
antibiotics were used.
1–2 ml of 1% lidocaine was infused before embolization
to prevent the embolic local pain.
SAP-MS particles suspended in sodium meglumine
ioxaglate 320 mgl/ml with concentration of 10 mg/ml
were injected through a microcatheter slowly under fluor-
oscopy guidance. Smaller particles (53–106, 106–150 μm)
were chosen at first, followed by larger particles (150–
212 μm).
The endpoint of embolization with SAP-MS was the
disappearance of the majority of tumor stain due to intra-
tumoral vessel occlusion. Gelatin sponge (GS) particles
were secondarily used to plug the proximal portion of the
feeding artery until complete cessation of the blood flow
could be seen under fluoroscopy guidance. As a rule, no
chemotherapeutic agent was used.
Additional sessions of embolization were performed
when skeletal pain recurred or radiological tumor re-
growth was recognized.
Evaluation and monitoring the patients’ symptom before
and after TAE
The changes in symptoms after TAE were evaluated by
retrospective review of medical charts using the ISOLS
evaluation form and the written record of the symptoms
(Table 2) by three orthopedic surgery co-authors. It is
based on the analysis of following the six factors (pain,
functional activities, emotional acceptance, external sup-
ports, walking abilities and gait) (Enneking et al. 1993). For
each of the six factors, values of 0 to 5 are assigned based
on established criteria. For each factor, specific values
(0,1,3,or 5) are equated with certain levels of achievement
or performance. Intermediate values of 2 or 4 are assigned,
based on the examiner’s judgment, when achievement or
Table 1 Patients’ list and clinical outcome























1 30 M RT 50 Gy
3 M before
initial TAE
3 118 17% 93% 9 × 9 × 7 5 × 5 × 4 −82.4 (+) Bil. LSAs,
Lt-5th LA
Alive
2 68 F RT 50 Gy
3 M after
final TAE
3 141 17% 80% 9 × 9 × 8 6 × 6 × 4 −77.8 (+) Bil. LSAs Alive
3 40 F 4 39 33% 96% 12 × 10 × 10 9 × 7 × 9 −52.3 (+) Bil. LSAs Alive
4 32 M Curretage
6 M before
initial TAE
5 14 46% died 7 × 7 × 9 9 × 12 × 18 340.8 (−) Bil. LSAs DOD
Tr. = treatment, RT = radiation therapy, M =months.
average (case1-3) = 99.3, M =months.
average (case1-3) = −70.8.
LSA = Lateral sacral artery, LA = Lumbar artery, Bi. = bilateral.














Table 2 ISOLS criteria specific to the lower extremity (Enneking et al. 1993)
Score Pain Function Emotional acceptance Support Walking ability Gait
5 No pain No restriction Rnthused None Unlimited Normal
4 Intermediate Intermediate Intermediate Intermediate Intermediate Intermediate
3 Modest/Non-disabling Recreational restriction Satisfied Brace LImited Minor cosmetic














Two cane or crutch Not independently Major handicap
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of the factors has been scored, the sum of the individual
factor scores is recorded.
The maximum possible score (number of factors
multiplied by five is recorded and the rating percentage
is determined by dividing the maximum score into theFigure 1 A 68-year-old female with GCT in the sacrum (Case 2). A. On
CT of same level as Figure 1A about 10 years after initial TAE, the size of thtotal score (Enneking et al. 1993). The radiographic change
after TAE was evaluated for occurrence of reossification by
X-ray image or CT and size reduction calculated three di-
mensionally by MR images.
The ISOLS score and imaging outcomes were assessed
in a final examination.CT, a large osteolytic mass occupied the sacrum (white arrows). B. On
e mass decreased and obvious reossification is shown (white arrows).
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The patients’ backgrounds and clinical outcomes are
summarized in Table 1.
All procedures (total 15 TAEs, mean three times) were
technically successful. The interval between each TAE
ranged from one month to nine months. In three pa-
tients, the ISOLS scores after the last TAE session were
more than 80%, and their symptoms remained improved
throughout the follow-up periods. In these three pa-
tients, mean volume reduction was 71% (range, 52.8%–
82.4%), and obvious reossification was observed after the
final TAE (Figures 1 and 2).
One patient died 14 months after the initial treatment
because of tumor growth in spite of repeated TAEs (case
4). In this case, pain relief and improvement of ADL
were only transient after TAE.
Post embolization syndromes (fever, local pain, or nau-
sea) remained in a conservatively controllable range.Figure 2 A 40-year-old female with GCT in the sacrum (Case 3). A. On
homogenous enhanced mass occupied the sacrum (white arrows). B. On d
in the sacrum (arrow). C. On digital sabtraction pelvic angiogram after TAE
stain is diminished (arrow). D. On contrast enhanced fat supressed T1-weig
pattern becomes inhomogenous compared with Figure 2A, which shows wIn one case (Case 1), permanent left-peroneal nerve
pulsy was observed after the third TAE, where the left
L5 lumbar artery was embolized.Discussion
Sacral GCT often presents as massive tumors (Lin et al.
2002). The size and location of the tumor make surgical
treatment difficult and dangerous. Radiation could be an
alternative treatment in the case of surgically unfavorable
sizes and locations (Lin et al. 2002), but secondary sar-
coma, although rare, can arise after radiation therapy in
such a wide radiation field (Nakanishi et al. 2001). There-
fore, TAE can be considered as one of the treatment op-
tions (Lackman et al. 2002; Martin and McCarthy 2010;
Lin et al. 2002; Hosalkar et al. 2007; Onishi et al. 2010;
Thangaraj et al. 2010). There are several reports on TAE
of sacral GCT. However, only a few reports focus on thecontrast enhanced fat supressed T1-weighted image of MRI, the
igital sabtraction pelvic angiogram, the hypervascular mass is shown
of bilateral lateral sacral arteries and middle sacral artery, the tumor
hted image of MRI about 14 months after initial TAE, the enhanced
hat appears to be a necrotic effect (white arrows).
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2013; Basile et al. 2004).
Early reports (Lackman et al. 2002; Lin et al. 2002;
Hosalkar et al. 2007; Onishi et al. 2010) described that
gelfoam, polyvinyl alcohol (PVA) particles and stainless
steel coil for TAE of sacral GCT were used. These conven-
tional materials were also used for pelvic tumors including
metastasis from renal cell carcinoma and aneurysmal bone
cyst (Chuang et al. 1979). However, these embolic mate-
rials have the following problems.
GS particles have the potential of short-term (weeks to a
month) proximal occlusion of a tumor-feeding artery
(Maeda et al. 2012; Osuga et al. 2008; Khankan et al. 2004).
PVA is the most commonly used permanent embolic
agent. However, the irregular-shaped PVA particles tend to
clump together leading to proximal vessel occlusion, which
is potentially the risk of non-target embolization and future
collateral development to the target lesion. In addition, the
organized thrombus in the spaces among PVA particles
can be partially recanalized. Basile et al. (Basile et al. 2004)
compared the efficacy of trisacryl gelatine microsphere
(TGM) versus PVA in the preoperative embolization of
bone neoplasms, and intraoperative blood loss volume was
significantly lower after embolizatioon with TGM than
after that with PVA. SAP-MS was originally designed for
TAE of hypervascular tumors. Osuga et al. described its
inertness and efficacy in TAE of large hepatocellular car-
cinoma (HCC) (Osuga et al. 2008; Laurent et al. 2004).
Precisely calibrated SAP-MS particles can penetrate intra-
tumoral vessels leading to long-term tumor devasculariza-
tion, whereas, the blood flow into the surrounding tissues
can be spared.
Such a targeted TAE using SAP-MS minimizes the risk
of ischemic damage of the normal tissues as shown by
histological evaluation.
Similarly, the use of calibrated microspheres have been
used to treat hypervascular tumors such as HCC as well
as uterine fibroid (Abramowitz et al. 2009; Maeda et al.
2012; Osuga et al. 2008; Khankan et al. 2004; Laurent
et al. 2004). Our primary aim was to accomplish more
peripheral arterial occlusion at the level of intra- or peri-
tumoral vessels using spherical embolic agents. GS parti-
cles were secondarily used to plug the proximal feeding
artery until complete cessation of the blood flow was ob-
tained. In our study, metalic coils were not used to allow
selective catheterization in the subsequent embolization.
Instead, the long term duration of devascularization and
symptom improvement were obtained by a relatively
small number of TAE sessions. In the previous reports,
TAE was repeated on schedule every 4–6 weeks until no
new vessel formation was evident (Lackman et al. 2002;
Hosalkar et al. 2007). In contrast, in our cases, excluding
the one fatal case, only three or four sessions of TAE
were needed during the follow-up period ranging 39–118 months (mean 99.3 mo). Favorable long-term out-
comes exceeding 100 months were obtained in two cases
(Case 1 and 2), although radiation therapy was added
prior to or after TAE. In one case (Case 1), left-peroneal
nerve pulsy was observed after embolization of left L5
lumbar artery, probably because of the ischemic damage
of the corresponding tissue.
In one case (case 4), pain relief and ADL improvement
were only transient after TAE. TAE could not control
the tumor progression, and the patient died 14 months
after the initial TAE. In this case, the tumor stain con-
sisted of fine vessels, and disappeared immediately after
only a small amount of embolic material was injected.
As a result, the necrotic effect was minimal on contrast-
enhanced MRI, and the tumor size increased rapidly.
We speculate that feeder occlusion at the proximal level
allowed collateral circulation to the residual tumors.
There are several limitations in this study. First, this is
a retrospecitve study with a small number of cases. In
two cases, the effectiveness of TAE may be influenced by
combination of the radiation therapy. There are no estab-
lished scores to evaluate the clinical conditions related to
the sacral GCT.
In conclusion, TAE can be considered as the treatment
option of choice for sacral GCT either alone or in conjunc-
tion with other therapy. In our experience, SAP-MS, a
spherical embolic agent, was a safe and effective material to
achieve peripheral tumor vessel occlusion resulting in long-
term symptom improvement and tumor size reduction.
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